Genetic Technologies - Stock Price History | GENE

Historical daily share price chart and data for Genetic Technologies since 2021 adjusted for splits. The latest closing stock price for Genetic Technologies as of September 24, 2021 is 3.36.
  • The all-time high Genetic Technologies stock closing price was 277.00 on November 07, 2005.
  • The Genetic Technologies 52-week high stock price is 8.18, which is 143.5% above the current share price.
  • The Genetic Technologies 52-week low stock price is 2.77, which is 17.6% below the current share price.
  • The average Genetic Technologies stock price for the last 52 weeks is 3.83.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Genetic Technologies Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 3.0802 2.0381 5.6700 1.4500 3.6000 80.90%
2019 2.6330 2.6108 5.5000 1.7000 1.9901 -8.98%
2018 4.8681 4.8800 7.4000 2.0480 2.1864 -52.88%
2017 3.9585 4.5600 6.9600 2.8000 4.6400 7.41%
2016 7.8996 10.2400 10.5800 4.2400 4.3200 -59.70%
2015 13.4328 7.6000 39.2800 5.0000 10.7200 39.18%
2014 19.6918 29.6000 40.0000 6.2080 7.7020 -73.07%
2013 46.6254 46.8000 65.2000 28.0000 28.6000 -34.40%
2012 65.9934 61.4000 115.2000 42.8000 43.6000 -28.05%
2011 94.9524 22.4000 206.0000 19.8100 60.6000 187.20%
2010 20.2506 23.6720 28.0020 13.6000 21.1000 -8.26%
2009 32.3064 21.0000 75.0000 17.4000 23.0000 9.52%
2008 49.8467 78.0000 88.3200 13.2000 21.0000 -73.82%
2007 98.2178 152.6000 159.0000 70.0000 80.2000 -49.62%
2006 162.8922 180.0000 219.8000 144.2000 159.2000 -12.43%
2005 223.6690 240.0000 277.0000 181.2000 181.8000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.052B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71